Search

Displaying results 1421 - 1430 of 4300 in total
  1. Drug

    Paraldehyde

    go.drugbank.com/drugs/DB09117
    ApprovedWithdrawn

    Paraldehyde is used as an ingredient in some cough medicines as an expectorant, but its efficacy for this indication has not been confirmed and its use as an expectorant may possibly be due to a placebo … Paraldehyde was initially introduced into medical practice in the United Kingdom in 1882 by the Italian physician Vincenzo Cervello.

  2. Drug

    Glycyrrhizic acid

    go.drugbank.com/drugs/DB13751
    ApprovedInvestigational

    [F80] It was approved by Health Canada to be used in over-the-counter products but all the products are currently on the status canceled post marketed.[L1113] … [A33062] From January 2014, glycyrrhizic acid as part of the licorice extract was approved by the FDA as an existing food sweetener.

  3. Drug

    Acoramidis

    go.drugbank.com/drugs/DB17999
    ApprovedInvestigational

    [A264808] It was brought to market by BridgeBio Pharma and approved by the FDA in November 2024 to reduce negative cardiovascular outcomes in patients with cardiomyopathy caused by TTR amyloidosis.

  4. Drug

    Oxilofrine

    go.drugbank.com/drugs/DB11610
    Approved

    It is currently marketed in Canada by Valeant under the tradename Cophylac.

  5. Drug

    Quinupristin

    go.drugbank.com/drugs/DB01369
    Approved

    Quinupristin/dalfopristin is a combination of two antibiotics used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium.

  6. Drug

    Cilastatin

    go.drugbank.com/drugs/DB01597
    ApprovedInvestigational

    The first combination product containing both drugs was approved by the FDA in November of 1985 under the trade name Primaxin, marketed by Merck & Co. … Since the antibiotic, [imipenem], is one such antibiotic that is hydrolyzed by dehydropeptidase, cilastatin is used in combination with imipenem to prevent its metabolism.

  7. Drug

    Interferon alfa-n1

    go.drugbank.com/drugs/DB00011
    ApprovedWithdrawn

    Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produc...

  8. Drug

    Autologous peripheral blood-derived CD34+ cells

    go.drugbank.com/drugs/DB16367
    ApprovedInvestigational

    Autologous peripheral blood-derived CD34+ cells, or CLBS119 (a proprietary version being developed by Caladrius Biosciences, Inc.), are hematopoietic stem cells. … [L27741] It is also a cell therapy being investigated by Caladrius Biosciences in the clinical trial NCT04522817 (CLBS119 for Repair of COVID-19 Induced Pulmonary Damage).

  9. Drug

    Ferric pyrophosphate citrate

    go.drugbank.com/drugs/DB13995
    Approved

    The ferric ion is strongly complexed by pyrophosphate and citrate.[A31979] FPC is categorized in Japan as a second class OTC drug.

  10. Drug

    Chymotrypsin

    go.drugbank.com/drugs/DB09375
    ApprovedInvestigationalVet approvedWithdrawn

    Chymotrypsin is the most abundant pancreatic proteases that represent up to 10-20% of the total protein synthesized by the exocrine pancreas [A32637].